Skip to main content
Clinical Trials/NCT00932477
NCT00932477
Completed
Not Applicable

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

Allergan0 sites47 target enrollmentAugust 2009

Overview

Phase
Not Applicable
Intervention
Glycerin and Polysorbate 80 based artificial tear
Conditions
Dry Eye Syndrome
Sponsor
Allergan
Enrollment
47
Primary Endpoint
Tolerability Questionnaire Mean Scores at 1 Week
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The safety and tolerability of two new artificial tears will be compared to a currently-available artificial tear in subjects with dry eye. Each subject will receive all three products in a randomly assigned order. The subject will use one product at a time for a duration of one week before switching to the next assigned product.

Registry
clinicaltrials.gov
Start Date
August 2009
End Date
September 2009
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Allergan
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Mild, moderate or severe symptoms of dry eye

Exclusion Criteria

  • Uncontrolled systemic disease
  • Contact lens wear
  • Participation in another clinical study

Arms & Interventions

Glycerin and Polysorbate 80 based artificial tear

Glycerin and Polysorbate 80 based artificial tear

Intervention: Glycerin and Polysorbate 80 based artificial tear

Outcomes

Primary Outcomes

Tolerability Questionnaire Mean Scores at 1 Week

Time Frame: 1 Week

Tolerability Questionnaire mean scores at 1 week. The Tolerability Questionnaire includes 8 tolerability questions on selected performance measures. All questions are scored based on continuous visual analog scale from 0-100. The first 4 questions presented measure increasing tolerability where 0=worst and 100=best. The second set of 4 questions presented measure decreasing tolerability where 0=best and 100=worst.

Secondary Outcomes

  • Number of Patients With at Least One Severity Grade Increase in Biomicroscopy Findings at 1 Week(1 Week)
  • Best-Corrected Visual Acuity (BCVA) Status at 1 Week(1 Week)
  • The Number of Ophthalmic Adverse Events at 1 Week(1 Week)

Similar Trials